TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: serum inflammatory marker Interleukine-8 (IL-8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum inflammatory marker TNF-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum inflammatory marker brain derived neurotrophic factor (BDNF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change in pain intensity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Bleeding-related Re-hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Perioperative Bleeding Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Brain function and structure using magnetic resonance imaging (MRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain and cognitive functioning assessment by electroencephalogram (EEG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive performance (DKEFS test battery)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Office Systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in Oxford Knee Score (OKS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: AUCτ,ss (area under the concentration-time curve of dabigatran in plasma at steady state over one dosing interval)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax,ss (maximum concentration of dabigatran in plasma at steady state)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ (area under the concentration-time curve of fexofenadine in plasma over the time interval from 0 to infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (maximum measured concentration of fexofenadine in plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Summed Pain Intensity Difference (SPID) at 0-8 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of elevated post-procedural peak CK-MB mass ratio values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Elastography (elasticity imagery)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infection with COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Three-dimensional gait assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Standardised Uptake Value (SUVmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Level of expression of HSP (HSP90, HSP70, HSP27)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Seroprevalence of neutralizing antibodies for type 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in the human microbiota during hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Live births after uterus transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Identification of New Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in CPAP Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 7-day Point Prevalence Smoking Abstinence Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Measure of Child Secondhand Smoke Exposure (SHSe)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinical benefit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: reduction in SAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in 6 minute hall walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in left LV end systolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improvement in echo-derived LV EF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of oxaliplatin and gemcitabine hydrochloride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of erlotinib hydrochloride and gemcitabine hydrochloride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum observed plasma drug concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in EEG effective connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in resting-state EEG coherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Auc0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to perform saphenous vein marking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Power of knee extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Functional MRI during movement of the shoulder and elbow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electroencephalography (EEG) during movement of the shoulder and elbow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin Peeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Irritant/Allergic Contact Dermatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Micro-eye movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electroencephalography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titers (GMT) of Serum Hemagglutination Inhibition (HAI) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving Hemagglutination Inhibition (HAI) Antibody Titer of 1:40 or Greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Short Maximum Speed Walk - Speed (SMSW-MaxS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who had sex without a condom
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants who had an STI
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants who increased knowledge concerning risks associated with unprotected sex
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: radiographic markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of F-IGA from Baseline to week 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of Surveys
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Major depressive episode severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: serum 25(OH)D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 1,25(OH)2D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in number of terminal hairs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major cardiovascular event rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of hematotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: end tidal partial pressure of carbon dioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: partial pressure of arterial carbon dioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: non-invasive blood pressure change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decayed, Missing, and Filled Tooth Surfaces (Dmfs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Change in knowledge in relation to physical activity
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Emotion Regulation Questionnaire (ERQ) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ruminative Response Scale (RRS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in QTc intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in overall cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in cerebral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of samples producing iPSCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Pancreatic Fluid Collection (PFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Viral clearance kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dry and healed draining hematoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECG (Electrocardiogram)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: C-SSRS (Columbia Suicidal Severity Rating Scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Uterine Natural Killer Cell levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: DNA methylation of genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence or absence of perivascular carotid artery enlargement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sustained virologic response (SVR) at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fractional Zinc absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in FPS-R scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physiological parameter of IOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physiological graph of IOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physiological parameter of IOS combining BDT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physiological graph of IOS combining BDT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COVID-19 symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physical frailty
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: psychological frailty
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Subjects Seroconverted for HI Antibodies Against Flu A/CAL/7/09 H1N1 Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Seroprotected for HI Antibodies Against Flu A/CAL/7/09 H1N1 Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HI Antibody Seroconversion Factors Against Flu A/CAL/7/09 H1N1 Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: International Physical Activity Questionnaire - Short Form
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Flamingo Balance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: significant liver fibrosis (score F3 and F4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of correction of dermal nasolabial fold wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Morphine equivalents (MOE) consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent time in therapeutic INR (TTR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically relevant respiratory tract infection or COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in skin roughness from baseline at week 4 and week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in skin wrinkle from baseline at week 4 and week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in skin hydration from baseline at week 4 and week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: main mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change in neurocognitive side effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motavizumab Concentration in Nasal Wash Aspirates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: operative difficulties
Endpoint domain: Adverse events/effects
Primary endpoint: post operative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Changes on airway epithelium cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Left ventricular global longitudinal strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Child social-emotional development
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Progression Events
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free survival for at least 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Objective tumor response (complete or partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adverse events deemed at least possibly related to treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Ratio of Dendritic Cells to Circulating Immature Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Medication Possession Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Focal attack severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration of abiraterone acetate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Route of delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Changes in Serum AST Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cognitive processes as assessed using Stroop test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive processes as assessed using D2 attention test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive processes as assessed using N back test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive processes as assessed using Trail making test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Onset sedation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Serum Bicarbonate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Brain Flortaucipir Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flortaucipir Whole Body Effective Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Reduced MAS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sustained Virological Response 12 Weeks Post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Step execution times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Analyte Concentration (AUC 0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oxidative stress after hCG and HMG treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total cholesterol levels after hCG treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of administering the adoptive T cell product
Endpoint domain: Adverse events/effects
Primary endpoint: Alloreactivity engendered by administering the adoptive T cell product
Endpoint domain: Adverse events/effects
Primary endpoint: Fetal Heart Rate Variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accelerations of Fetal Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline sputum culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: The proportion of eligible patients who agreed to participate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: The proportion of patients included in the study who answered the follow-up questionnaire at one month
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: The proportion of patients at follow-up who consumed alcohol at least once in the last 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Dose for Expansion (RDE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Case Management Sessions Completed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: laboratory data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receipt of blood transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cardiorespiratory exercise test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness of skin graft techniques for post burn wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of patients requiring endotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: antitumor activity of ifinatamab deruxtecan (I-DXd)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Highest Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indications for abdominal plain x-ray prescription
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with sPGA score of clear or almost clear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with a ≥ 90% reduction from Baseline PASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Eating Disorder Diagnostic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase of peak VO2 consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of itraconazole treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Probing Depth (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Uric Acid Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma sitosterol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Achieving MAS Remission at Week 8 After Initiation of Emapalumab Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First MAS Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistence of memory B cells in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Treatment-related Grade 3 or 4 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of severe infection
Endpoint domain: Adverse events/effects
Primary endpoint: Days Alive and Out of Hospital
Endpoint domain: Mortality/survival
Primary endpoint: Amounts of immune cell biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes